Company profile: HotSpot Therapeutics
1.1 - Company Overview
Company description
- Provider of the Smart Allostery Platform to identify hotspots and design allosteric modulators by integrating biology, computational sciences, chemistry and biophysics; with programs: HST-1011, an investigational oral allosteric CBL-B inhibitor in Phase 1 for solid tumors, and HST-1021, a potential first-in-class MALT1 scaffolding inhibitor for hematological malignancies and selected solid tumors with preclinical tumor growth inhibition.
Products and services
- HST-1011: A clinical-stage investigational oral small-molecule allosteric inhibitor targeting CBL-B, engineered for treating patients with solid tumors and presently evaluated in Phase 1 clinical trials
- Smart Allostery Platform: A computationally integrated technology that systematically identifies natural hotspots and architects potent, selective allosteric modulators by combining insights from biology, computational sciences, chemistry, and biophysics
- HST-1021: A preclinical-stage potential first-in-class allosteric inhibitor targeting MALT1 scaffolding function, developed to treat hematological malignancies and selected solid tumors, with demonstrated preclinical tumor growth inhibition
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to HotSpot Therapeutics
Atomwise
HQ: United States
Website
- Description: Provider of AI and deep learning–based, structure‑based drug discovery solutions, leveraging supercomputers to identify small‑molecule candidates. Offers AtomNet technology to streamline discovery and develop a pipeline of drug candidates advancing into preclinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atomwise company profile →
GRO Biosciences
HQ: United States
Website
- Description: Provider of protein therapeutics technology leveraging Genomically Recoded Organisms to produce non-standard amino acid proteins. Offers the GRO Platform to expand the amino acid alphabet; a Biofoundry integrating computational design and robotics; DuraLogic chemistry to enhance protein structure and duration; and ProGly to modulate immune responses, aiming to treat autoimmunity and reduce anti-drug antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GRO Biosciences company profile →
Evozyne
HQ: United States
Website
- Description: Provider of generative AI-driven protein design and engineering solutions for therapeutic discovery and drug development, including ProT-VAE (co-developed with NVIDIA) to design therapeutic proteins, protein engineering for rare diseases (in partnership with Takeda), evolutionary deep learning to create novel proteins, and computational chemistry to optimize protein stability and function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Evozyne company profile →
Qumas
HQ: United States
Website
- Description: Provider of a closed-loop compliance model that standardizes and integrates common elements of compliance tasks across the organization, enabling enterprises to converge compliance programs onto a single platform to reduce compliance costs and create competitive advantage.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Qumas company profile →
Lab Unlimited
HQ: Ireland
Website
- Description: Provider of laboratory instrumentation, consumables, training, service, and validation, with an extensive catalogue available on its website backed by more than 400 manufacturers. Highly trained representatives can recommend solutions, replacements, and cost-saving options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lab Unlimited company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for HotSpot Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to HotSpot Therapeutics
2.2 - Growth funds investing in similar companies to HotSpot Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for HotSpot Therapeutics
4.2 - Public trading comparable groups for HotSpot Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →